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 WSU Medical Student Research Symposium Abstract  
 
Purpose: Our lab has been focused on developing thymosin beta-4 (Tβ4 ) as a potential 
therapeutic for bacterial keratitis, an extremely debilitating ocular infection that is prevalent 
world wide. Tβ4 is a naturally occurring g-actin sequestering peptide, which we have previously 
shown significantly improves disease outcome in a P. aeruginosa (PA)-induced keratitis model 
when used adjunctively with ciprofloxacin (cipro). Following observations of decreased bacterial 
load in Tβ4 +cipro-treated corneas, this project aims to investigate the synergy between Tβ4 and 
cipro regarding bactericidal effects and antimicrobial peptide (AMP) regulation. 
Methods: Minimum inhibitory concentration (MIC) assays were used to quantify the bactericidal 
activity of ciprofloxacin, Tβ4, and a combination of cipro with Tβ4 to evaluate synergy. Micro 
serial dilutions were carried out using 96 well plates and concentrations of PA prepared for 105 
and 106 CFU/mL inoculum. Additionally, we began to further elucidate the mechanism behind 
Tβ4 mediated effects by assessing the impact of Tβ4 on the activation of AMP pathways. Human 
corneal epithelial cells (HUCLs) were stimulated with LPS (25 μg/mL) for 6 and 24 hours. 
Experimental groups included: CTRL, Tβ4, cipro, and Tβ4 +cipro. Additionally, mRNA and protein 
levels of AMPs, including LL-37, S100A8, hBD-3, keratin6A, and TLR-4 were also assessed. 
Results: Though we expected to see a further decrease in MIC for adjunct Tβ4 therapy in 
comparison with cipro alone, the two groups exhibited similar results without a significant 
difference in MIC. Surprisingly however, the MIC assay showed very little bacterial growth  with 
ciprofloxacin alone, even at significantly low concentrations. Unexpectedly, Tβ4 alone did not 
show significant bactericidal activity. Regarding AMP expression, RT-PCR results revealed 
upregulation of a number of AMPs in response to Tβ4 stimulation at 6 hrs, as well as further 
upregulation in combo groups at 24 hrs, indicating a possible synergistic effect. This trend has 
been similarly observed with select lipoxygenase enzymes and SPM receptors.  
Conclusion: We believe that the results from our experiments help provide evidence by which 
Tb4 influences the antimicrobial effects observed in the bacterial keratitis model. More 
importantly, suggestions of a synergistic effect between Tb4 and cipro at the gene level, as well 
as findings of an extremely low MIC for ciprofloxacin may allow for lower concentrations of 
antibiotic to be used in the clinical setting. This would not only decrease the risk for potential 
side effects/toxicity issues related to the use of antibiotics, but potentially reduce antimicrobial 
resistance.  
 
 
 
